

Food and Drug Administration
Rockville MD 20857

JAN 31 1997

Re: DECTOMAX
Docket No. 96E-0387

RECEIVED #27

FEB 7 1997

PATENT EXTENSION
A/C PATENTS

- The Honorable Bruce Lehman
Assistant Secretary of Commerce and
Commissioner of Patents and Trademarks
Box Pat. Ext.
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Commissioner Lehman:

This is in regard to the application for patent term extension for U.S. Patent No. 5,089,480, filed by Pfizer, Inc., under 35 U.S.C. § 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for DECTOMAX, the animal drug product claimed by the patent.

The total length of the review period for DECTOMAX is 2,836 days. Of this time, 2,695 days occurred during the testing phase and 141 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 512(j) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: October 26, 1988.

The applicant claims December 7, 1988 as the date the Investigational New Animal Drug application (INAD) became effective. However, FDA records indicate that the date of FDA's official acknowledgment letter assigning a number to the INAD was October 26, 1988, which is considered to be the effective date for the INAD.

2. The date the application was initially submitted with respect to the animal drug product under subsection 512(b) of the Federal Food, Drug, and Cosmetic Act: March 12, 1996.

The applicant claims March 7, 1996, as the date the New Animal Drug Application (NADA) for DECTOMAX (NADA 141-061) was initially submitted. However, a review of FDA records reveals that the date of FDA's official acknowledgement letter assigning a number to the NADA was March 12, 1996, which is considered to be the initially submitted date for the NADA.

3. The date the application was approved: July 30, 1996.

FDA has verified the applicant's claim that NADA 141-061 was approved on July 30, 1996.

DECTOMAX - Page 2

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in dark ink, appearing to read "Stuart L. Nightingale", written in a cursive style.

Stuart L. Nightingale, M.D.
Associate Commissioner
for Health Affairs

cc: J. Trevor Lumb
Pfizer, Inc.
Patent Department
235 East 42nd St.
New York, NY 10017-5755